Strategies for mucosal vaccine development

American Journal of Tropical Medicine and Hygiene

Volumn 60, Issue 4 SUPPL., 1999, Pages 35-45

  Boyaka, Prosper N ^a   Marinaro, Mariarosaria ^a   Vancott, John L ^a   Takahashi, Ichiro ^b   Fujihashi, Kohtaro ^a   Yamamoto, Masafumi ^b   Van Ginkel, Frederik W ^a   Jackson, Raymond J ^a   Kiyono, Hiroshi ^a,b   McGhee, Jerry R ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6;

CONFERENCE PAPER; CYTOKINE PRODUCTION; HOST RESISTANCE; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; INFECTION RESISTANCE; INTESTINE LYMPHATIC TISSUE; RETICULOENDOTHELIAL SYSTEM; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION;

EID: 0032953125     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1999.60.35     Document Type: Conference Paper

References (117)

1. Mowat A.McI, 1994. Oral tolerance and regulation of immunity to dietary antigens. Ogra PL, Mestecky J, Lamm MF, Strober W, McGhee JR, Bienenstock J, eds. Handbook of Mucosal Immunology. San Diego: Academic Press, Inc., 185-201.
2. Mosmann TR, Coffman RL, 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7: 145-173.
3. + T cells. Annu Rev Immunol 12: 635-673.
4. Romagnani S, 1994. Lymphokine production by human T cells in disease states. Anna Rev Immunol 12: 227-257.
5. Finkelman FD, Holmes J, Katona IM, Urban Jr JF, Beckmann MP, Park LS, Schooley KA, Coffman RL, Mosmann TR, Paul WE, 1990. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 8: 303-333.
6. Staats HF, Jackson RJ, Marinaro M, Takahashi I, Kiyono H, McGhee JR, 1994. Mucosal immunity to infection with implication for vaccine development. Curr Opin Immunol 6: 572-583.
7. Wolf JL, Rubin DH, Finberg R, Kauffman RS, Sharpe AH, Trier JS, Fields BN, 1981. Intestinal M cells: a pathway for entry of reovirus into the host. Science 212: 471-472.
8. Owen RL, 1994. M cells-entry ways of opportunity for enteropathogens. J Exp Med 180: 7-9.
9. Brandtzaeg P, 1995. Molecular and cellular aspects of the secretory immunoglobulin system. APMIS 103:1-19.
10. Ruggeri FM, Johansen K, Basile G, Kraehenbul P, Svensson L, 1995. Antirotavirus imunoglobulin A neutralizes virus in vitro after transcytosis through epithelial cells and protects infant mice from diarrhea. J Virol 72: 2708-2714.
11. Guy-Grand D, Malassis-Seri M, Briottet C, Vassalli P, 1991. Cytotoxic differentiation of mouse gut thymodependent and independent intraepithelial T lymphocytes is induced locally. Correlation between functional assays, presence of perform and granzyme transcripts, and cytoplasmic granules. J Exp Med 173: 1549-1552.
12. + gut intraepithelial lymphocytes, lytic for parasite-infected enterocytes. J Immunol 153: 4596-4603.
13. Croitoru K, Bienenstock J, 1994. Characteristics and functions of mucosal-associated lymphoid tissue. Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, eds. Handbook of Mucosal Immunology. San Diego: Academic Press, Inc. 141-149.
14. Elson CO, Ealding W, 1984. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 133: 2892-2897.
15. Lycke N, Holmgren J, 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune response to orally presented antigens. Immunology 59: 301-308.
16. Bromander AK, Kjerrulf M, Holmgren J, Lycke N, 1993. Cholera toxin enhances alloantigen presentation by cultured intestinal epithelial cells. Scand J Immunol 37: 452-458.
17. McGee DW, Elson CO, McGhee JR, 1993. Enhancing effect of cholera toxin on interleukine-6 secretion by IEC-6 intestinal epithelial cells: mode of action and augmenting effect of inflammatory cytokines. Infect Immun 61: 4637-4644.
18. Leal-Berumen I, Snider DP, Baraas-Lopez C, Marshall JS, 1996. Cholera toxin increases IL-6 synthesis and decreases TNF-α production by rat peritoneal mast-cells. J Immunol 156: 316-321.
19. Bromander A, Holmgren J, Lycke N, 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 146: 2908-2914.
20. Lycke N, Strober W, 1989. Cholera toxin promotes B cell isotype differentiation. J Immunol 142: 3781-3787.
21. Woogen SD, Turo K, Dieleman LA, Beagley KW, Elson CO, 1993. Inhibition of murine T-cell activation by cholera toxin B subunit is not mediated through the phosphatidylinositol second messenger system. J Immunol 150: 3274-3283.
22. Elson CO, Holland SP, Dertzbaugh MT, Cuff CF, Anderson AO, 1995. Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit. J Immunol 154: 1032-1040.
23. Watts TH, Alaverdi N, Wade WF, Linsley PS, 1993. Induction of costimulator molecule B7 in M12 lymphoma by cAMP or MHC restricted T cell interactions. J Immunol 150: 2192-2202.
24. Cong Y, Weaver CT, Elson CO, 1997. The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective upregulation of B7.2 expression. J Immunol 159: 5301-5308.
25. Nunes J, Bagnasco M, Lopez M, Lipcey C, Mawa S, Olive D, 1991. Dissociation between early and late events in T cell activation mediated through CD28 surface molecules. Mol Immunol 28: 427-435.
26. Xu-Amano J, Kiyono H, Jackson RJ, Staats HF, Fujihashi K, Burrows PD, Elson CO, Pillai S, McGhee JR, 1993. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 178: 1309-1320.
27. Marinaro M, Staats HF, Hiroi T, Jackson RJ, Coste M, Boyaka PN, Okahashi N, Yamamoto M, Kiyono H, Bluethmann H, Fujihashi K, McGhee JR, 1995. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol 155: 4621-4629.
28. Jackson RJ, Fujihashi K, Xu-Amano J, Kiyono H, Elson CO, McGhee JR, 1993. Optimization of oral vaccines: induction of systemic and mucosal B cells and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun 61: 4272-4279.
29. Wilson AD, Bailey M, Williams NA, Stokes CR, 1991. The in vitro production of cytokines by mucosal lymphocytes immunized by oral administration of keyhole limpet hemocyanin using cholera toxin as adjuvant. Eur J Immunol 21: 2333-2339.
30. Hornquist E, Lycke N, 1993. Cholera toxin greatly promotes antigen-priming T cells. Eur J Immunol 23: 2136-2143.
31. Snider DP, Marshall JS, Perdue MH, Liang H, 1994. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein antigen and cholera toxin. J Immunol 153: 647-657.
32. Vajdy M, Kosco-Vilbois MH, Kopf M, Köhler, Lycke N, 1995. Impaired mucosal immune response in interleukin 4-targeted mice. J Exp Med 181: 41-53.
33. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A. Infect Immun 64: 1516-1526.
34. Levine MM, Kaper JB, Black RE, Clements ML, 1983. New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev 47: 510-550.
35. Yamamoto S, Takeda Y, Yamamoto M, Kurazono H, Imaoka K, Yamamoto M, Fujihashi K, Noda M, Kiyono H, McGhee JR, 1997. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med 185: 1203-1210.
36. Yamamoto S, Kiyono H, Yamamoto M, Imaoka K, Fujihashi K, van Ginkel FW, Noda M, Takeda S, McGhee JR, 1997. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 94: 5267-5672.
37. Douce G, Fontana M, Pizza M, Rappuoli R, Dougan G, 1997. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun 65: 2821-2828.
38. Robinson K, Bellaby T, Wakelin D, 1995. Efficacy of oral vaccination against the murine intestinal parasite Trichuris muris is dependent upon host genetics. Infect Immun 63: 1762-1766.
39. Akhiani AA, Nilsson LA, Oucherlony O, 1993. Effect of cholera toxin on vaccine-induced immunity in murine schistosomiasis mansoni. Infect Immun 61: 4919-4924.
40. Spangler BD, 1992. Structure function of cholera toxin and related Escherichia coli heat-labile enterotoxins. Microbiol Rev 56: 622-647.
41. Clements JD, Hartzog NM, Lyon FL, 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigen. Vaccine 6: 269-277.
42. Nagakawa I, Takahashi I, Kiyono H, McGhee JR, Hamada S, 1996. Mucosal immunity: Escherichia coli labile toxin induces early Th1 and late Th2 cytokine expression in Peyer's patches. J Infect Dis 173: 1423-1436.
43. Takahashi I, Marinaro M, Kiyono H, Jackson RJ, Nakagawa I, Fujihashi K, Hamada S, Clements JD, Bost KL, McGhee JR, 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis 173: 627-635.
44. Tsuji T, Inoue T, Miyama A, Okamoto K, Honda T, Miwatani T, 1990. A single amino acid substitution in the A subunit of Escherichia coli enterotoxin results in a loss of its toxic activity. J Biol Chem 265: 22520-22525.
45. Lycke N, Tsuji T, Holmgren J, 1992. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 22: 2277-2281.
46. Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, Domenghini M, Rappuoli R, Dougan G, 1995. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 92: 1644-1648.
47. Dickinson BL, Clements JD, 1995. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63: 1617-1623.
48. Chatfield SN, Charles IG, Makoff AJ, Oxer MD, Dougan G, Pickard D, Slater D, Fairweather NF, 1992. Use of the nirB promotor to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single dose oral tetanus vaccine. Bio/Technology 10: 888-892.
49. Curtiss III R, Kelly SM, Hassan JO, 1993. Live oral avirulent Salmonella vaccines. Vet Microbiol 37: 397-405.
50. Ramarathinam L, Niesel DW, Kimpel GR, 1993. Salmonella typhimurium induces IFN gamma production in murine splenocytes. Role of natural killer cells and macrophages. J Immunol 150: 3973-3981.
51. Scott P, 1991. IFN-γ modulates the early development of Th1 and Th2 responses in a murine model of cutaneous Leishmaniasis J Immunol 147: 3149-3155.
52. Flesch I, Kaufmann SH, 1987. Mycobacterial growth inhibition by interferon-gamma activated bone marrow macrophages and differential susceptibility among strains of M. tuberculosis. J Immunol 138: 4408-4413.
53. Van Cott JL, Staats HF, Pascual DW, Roberts M, Chatfield SN, Yamamoto M, Carter PB, Kiyono H, McGhee JR, 1996. Regulation of mucosal and systemic antibody responses by T helper cells subsets, macrophages and derived cytokines following oral immunization with live recombinant Salmonella. J Immunol 156: 1504-1514.
54. Coffman RL, Shrader B, Carty J, Mosmann TR, Bond MW, 1987. A mouse T cell product that preferentially enhances IgA production. I. Biologic characterization. J Immunol 139: 3685-3690.
55. Beagley KW, Eldridge JH, Kiyono H, Everson MP, Koopman WJ, Honjo T, McGhee JR, 1989. Interleukins and IgA synthesis: human and murine IL-6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med 169: 2133-2148.
56. Briére F, Bridon J-M, Chevet D, Souillet G, Bienvenu F, Guret C, Martinez-Valdez H, Banchereau J, 1994. Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. J Clin Invest 94: 97-104.
57. Takahashi I, Kiyono H, Jackson RJ, Fujihashi K, Staats HF, Hamada S, Clements JD, Bost KL, McGhee JR, 1996. Epitope maps of Escherichia coli labile toxin B subunit for development of a synthetic oral vaccine. Infect Immun 64: 1290-1298.
58. Buchmeier NA, Heffron F, 1990. Induction of Salmonella stress proteins upon infection of macrophages. Science 248: 730-732.
59. el Guink N, Kris RM, Goodman-Snitkoff G, Small PA, Mannino RJ, 1989. Intranasal immunization with proteoliposomes protects against influenza. Vaccine 7: 147-151.
60. Hirabayashi Y, Kurata H, Funato H, Nagamine R, Arawa C, Tamura S, Shimada K, Kurata T, 1990. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine 8: 243-248.
61. Abraham E, 1992. Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response. Vaccine 10: 461-468.
62. van Ginkel FW, Liu C, Simecka JW, Dong JY, Greenway T, Frizzell RA, Kiyono H, McGhee JR, Pascual DW, 1995. Intratracheal gene delivery with adenoviral vectors induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum Gene Ther 6: 895-903.
63. van Ginkel FW, McGhee JR, Liu C, Simecka JW, Yamamoto M, Frizzell RA, Sorscher EJ, Kiyono H, Pascual DW, 1997. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and its transgene. J Immunol 159: 685-693.
64. Coutelier JR Coulie PG, Wanters P, Hereman H, van der Lought JTM, 1990. In vivo polyclonal B-lymphocytes activation elicited by murine viruses. J Virol 64: 5383-5388.
65. Yang Y, Li Q, Ertl HC, Wilson JM, 1995. Cellular and humoral immune responses to viral antigens clear barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 69: 2004-2015.
66. Livingston JB, Lu S, Robinson H, Anderson DJ, 1998. Immunization of the femal genital tract with a DNA-based vaccine. Infect Immun 66: 322-329.
67. Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL, 1993. DNA vaccines: protective immunization by parenteral, mucosal and gene-gun inoculations. Proc Natl Acad Sci USA 90: 11478-11482.
68. Ulmer JB, Donelly JB, Parker SE, Rholdes GH, Felgner PL, Swarki VJ, Gromkoski SH, Deck RR, De Witt CM, Friedman A, Hawa LA, Leader KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, Kiu MA, 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749.
69. Wolf JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felger PL, 1990. Direct gene transfer into muscle in vivo. Science 247: 1465-1468.
70. Wang B, Ugen E, Srikantan V, Agadjanyan MG, Dang K, Refaeli T, Sata AL, Williams WV, Weinter DB, 1993. Gene inoculation generates immune responses against human immunodeficiency virus type I. Proc Natl Acad Sci USA 90: 4156-4160.
71. Jackson RJ, Staats HF, Xu-Amano J, Takahashi I, Kiyono H, Hudson ME, Gilley RM, Chatfield SN, McGhee JR, 1994. Oral vaccine models: multiple delivery systems employing tetanus toxoid. Ann NY Acad Sci 730: 217-234.
72. Chen SC, Jones DH, Fynan EF, Farrar GH, Clegg JC, Greenberg HB, Herrmann JE, 1998. Protective immunity induced by oral immunization with a rotavirus D vaccine encapsulated in microparticles. J Virol 72: 5757-5761.
73. Sasaki S, Hamajima K, Fukushima J, Ihata A, Ishii N, Gorai I, Hirahara F, Mohri H, Okuda K, 1998. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine. Infect Immun 66: 823-826.
74. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH, 1998. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by co-delivery of cytokine genes. J Immunol 160: 1320-1339.
75. Waine G, Yang W, Scott JC, McManus DP, Kalinna BH, 1998. DNA-based vaccination using Schistosoma japonicum (Asian blood-flu) genes. Vaccine 15: 846-848.
76. Bland PW, Warren LG, 1986. Antigen presentation by epithelial cells in the rat intestine. 1. Kinetics, antigen specificity and blocking by anti-Ia antisera. Immunology 58: 1-7.
77. + T cells. Ear J Immunol 19: 1513-1516.
78. High N, Mounier J, Prevost RC, Sansonetti PJ, 1992. 1pa B of Shigella flexneri causes entry into epithelial cells and escape from the phagocytic vacuole. EMBO J II: 1991-1999.
79. Hedges S, Svenson M, Svanborg C, 1992. Interleukin-6 response of epithelial cell lines to bacterial stimulation in vitro. Infect Immun 60: 1295-1301.
80. Jung HC, Eckmann L, Yang S, Panja A, Fierer J, Morzycka-Wroblewska E, Kagnoff MF, 1995. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest 95: 55-65.
81. Cerf-Bensussan N, Quaroni A, Kurnick JT, Bhan AK, 1984. Intraepithelial lymphocytes modulates Ia expression by intestinal epithelial cells. J Immunol 132: 2244-2252.
82. Mayer L, Eisenhardt D, Salomon P, Bauer W, Pious R, Piccinini L, 1991. Expression of class II molecules on intestinal epithelial cells in humans. Gastroentemlogy 100: 3-12.
83. McGee DW, Aicher WK, Eldridge JH, Peppard JV, Mestecky J, McGhee JR, 1991. Transforming growth factors enhances secretory component and major histocompatibility complex class I antigen expression on rat IEC-6 intestinal epithelial cells. Cytokines 3: 543-550.
84. McGee DW, Beagley KW, Aicher WK, McGhee JR, 1992. Transforming growth factors enhances interleukin-6 secretion by intestine epithelial cells. Immunology 77: 7-12.
85. Phillips JO, Everson MP, Moldoveanu Z, Lue C, Mestecky J, 1990. Synergistic effect of IL-4 and interferon-γ on the expression of polymeric Ig receptor (secretory component) and IgA binding by human epithelial cells. J Immunol 145: 1740-1744.
86. McGee DW, Bamberg T, Vitkus SJD, McGhee JR, 1995. A synergistic relationship between TNF-α, IL-1β and TGF-β1 on IL-6 secretion by the IEC-6 intestinal epithelial cell line. Immunology 85: 6-11.
87. Kawabata S, Boyaka PN, Coste M, Fujihashi K, Yamamoto M, McGhee JR, Kiyono H, 1998. Intraepithelial lymphocytes from villus tip and crypt portions of the murine small intestine show distinct characteristics. Gastroenterologv 115: 1-10.
88. Goodman T, Lefrancois L, 1988. Expression of the γδ T cell receptor on intestinal CDS intraepithelial lymphocytes. Nature 333: 855-858.
89. Mombaerts P, Amoldi J, Russ F, Tonegawa S, Kauffmann SHE, 1993. Different roles of αβ and γδ T cells in immunity against intracellular bacterial pathogens. Nature 365: 53-56.
90. Bonneville M, Janeway Jr CA, Ito K, Haser W, Ishida I, Nakanishi N, Tonegawa S, 1988. Intestinal intraepithelial lymphocytes are a distinct set of γδ T cells. Nature 336: 479-481.
91. Guy-Grand D, Cerf-Bensussan N, Malissen B, Malassis-Seris M, Briottet C, Vassalli P, 1991. Two gut intraepithelial CDS lymphocyte populations with different T cell receptors: a role for the gut epithelium in T cell differentiation. J Exp Med 173: 471-481.
92. Komano H, Fujiura Y, Kawaguchi M, Matsumoto S, Hashimoto Y, Oana S, Mombaert P, Tonegawa S, Yamamoto H, Itohara S, Nanno M, Ishikawa H, 1995. Homeostatic regulation of intestinal epithelia by intraepithelial γδ T cells. Proc Natl Acad Sci USA 92: 6147-6151.
93. Fujihashi K, McGhee JR, Kweon M, Cooper MD, Tonegawa S, Takahashi I, Hiroi T, Mestecky J, Kiyono H, 1996. γδ T cell deficient mice have impaired mucosal IgA responses. J Exp Med 183: 1929-1935.
94. + intraepithelial lymphocytes. Proc Natl Acad Sci USA 93: 3613-3618.
95. Watanabe M, Ueno Y, Yajima T, Iwao Y, Tsuchiya M, Ishikawa H, Aiso S, Hibi T, Ishii H, 1995. Interleukin 7 is produced by human intestinal epithelial cells and regulate the proliferation of intestinal mucosal lymphocytes. J Clin Invest 95: 2945-2953.
96. Mombaerts P, Miroguchi E, Grosby MJ, Glimcha LH, Bhan AK, Tonegawa S, 1993. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75: 274-282.
97. Sadlack B, Neiz H, Schorle H, Schimpt A, Feller AC, Horak I, 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75: 253-261.
98. Kuhn R, Lohler J, Rennick D, Rajwesky K, Nuller W, 1993. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 75: 263-274.
99. Kaufmann SH, Ladel CH, 1994. Application of knockout mice to the experimental analysis of infections with bacteria and protozoa. Trends Microbiol 2: 235-242.
100. Van Cott JL, Chatfield SN, Roberts M, Hone DM, Hohmann EL, Pascual DW, Yamamoto M, Kiyono H, McGhee JR, 1998. Regulation of host immune responses by modification of Salmonella virulence genes. Nature Med 4: 1247-1252.
101. Muotiala A, Makela PH, 1990. The role of IFN-γ in murine Salmonella typhimurium infection. Microb Pathog 8: 135-141.
102. McGhee JR, Mestecky J, Elson CO, Kiyono H, 1989. Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol 9: 175-199.
103. Ramsay AJ, Husband AJ, Ramshaw IA, Boa S, Matthaei KI, Koehler G, Kopf M, 1994. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264: 561-563.
104. Fattori E, Cappelletti M, Costa P, Sellito C, Cantoni L, Carelli M, Faggioni R, Fantuzzi G, Ghezzi P, Poli V, 1994. Defective inflammatory response in interleukin 6-deficient mice. J Exp Med 180: 1243-1250.
105. Kroese FG, Butcher EC, Stall AM, Lalor PA, Adams S, Herzenberg LA, 1989. Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int Immunol 1: 75-84.
106. Bromander AK, Ekman L, Kopf M, Nedrud G, Lycke NY, 1996. IL-6-deficient mice exhibit normal IgA responses to local immunization and Helicobacter felis infection. Immunology 156: 4290-4297.
107. Trinchieri G, 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Anna Rev Immunol 13: 251-276.
108. Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, Anderson TD, Sarmiento U, Hubbard BR, Murphy M, 1994. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocytes activity and induces production of IFN gamma in vivo. Int Immunol 6: 157-167.
109. Germann T, Szeliga J, Hess H, Storkel S, Podlaski FJ, Gately MK, Schmitt E, Rude E, 1995. Administration of interleukin-12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 92: 4823-4827.
110. Marinaro M, Boyaka PN, Finkelman FD, Kiyono H, Jackson RJ, Jirillo E, McGhee JR, 1997. Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J Exp Med 185: 415-427.
111. Marinaro M, Boyaka PN, Jackson RJ, Finkelman FD, Kiyono H, Jirillo E, McGhee JR, 1999. Use of intranasal IL-12 to target predominantly Th1 responses to nasal and Th2 responses to oral vaccines given with cholera toxin. J Immunol 162: 114-121.
112. Metzger DW, McNutt RM, Collins JT, Buchanan JM, Van CV, Dunnick WA, 1997. Interleukin-12 acts as an adjuvant for humoral immunity through interferon-gamma-dependent and -independent mechanisms. Eur J Immunol 27: 1958-1965.
113. Germann T, Guckes S, Bongartz M, Dlugonska H, Schmitt E, Kolbe L, Kolsch E, Podlaski FJ, Gately MK, Rude E, 1995. Administration of IL-12 during ongoing immune responses fails to permanently suppress and can even enhance the synthesis of antigen-specific IgE. Int Immunol 7: 1649-1657.
114. Finkelman FD, Madden KB, Cheever AW, Katona IM, Morris SC, Gately MK, Hubbard BR, Gause WC, Urban JF, 1994. Effects of interleukin 12 on immune responses and host protection in mice infected with intestinal nematode parasites. J Exp Med 179: 1563-1572.
115. + T cells. J Immunol 159: 591-598.
116. Li L, Young D, Wolf SF, Choi YS, 1996. Interleukin-12 stimulates B cell growth by inducing IFN-gamma. Cell Immunol 168: 133-139.
117. Boyaka PN, Marinaro M, Jackson RJ, Menon S, Kiyono H, McGhee JR, 1999. Interteukin 12 is an effective adjuvant for induction of mucosal immunity. J Immunol 162: 122-128.